You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Madras HC notice to Centre on plea to declare Serum's Covishield jab unsafe

Litigant is a Chennai-based consultant who volunteered for the trial. Claims he suffered side effects, for which he sought a compensation of Rs 5 cr

Topics
Coronavirus | Coronavirus Tests | Coronavirus Vaccine

T E Narasimhan  |  Chennai 

New Delhi: The first batch of Covishield vaccine reaches central storage facility at Rajiv Gandhi Super Specialty hospital in New Delhi, Tuesday, Jan. 12, 2021. (PTI Photo/ Kamal Kishore)
He claimed he filed the plea when his health condition worsened after taking Serum's vaccine

The today issued a notice to the Centre on a petition to declare the Serum Institute's Covishield vaccine unsafe.

The notice was issued in response to a writ petition filed by a Chennai-based business consultant who volunteered for the trial. He claims he suffered from side effects, for which he sought a compensation of Rs 5 crore.

Legal team representing the Serum Institute said, "Allegations made in the petition are unfounded and frivolous. Serum will respond to same appropriately before the "

In November 2020, the litigant sent a legal notice to Serum Institute of India (Serum) seeking a compensation of Rs 5 crore and asked the Government and ICMR not to approve the manufacture and distribution of the vaccine.

He claimed he filed the plea when his health condition worsened after taking Serum's vaccine. In turn, Serum sent a notice asking for Rs 100 crore compensation from the litigant.

The litigant has now filed a petition, a copy of which is available with Business Standard, asking the to declare that the severe side effects and the hospitalisation of the Petitioner from October 11 to October 26 constituted a “serious adverse event” caused by the administration of trial vaccine. The Petitioner claimed he took the jab as a volunteer on October 1, 2020.

".....serious adverse reactions on me one after another, after taking the trial vaccine prima facie prove that the vaccine is not safe and could have serious side effects. Therefore the balance of convenience is in favour of stopping the administration of continuance of vaccines to the public. Hence it is prayed that the Hon’ble Court may be pleased to grant an ad interim injunction restraining the 1st and 2nd Respondents from continuing administering the ‘Covishield' vaccine manufactured by the 4th Respondent (Serum) to the public pending final disposal of the Writ Petition," stated in the petition.

He also stated that he took an opinion of the experts in the field and they have said the serious adverse reaction occurred to him was due to the trial vaccine that was administered to me on October 1, 2020.

The petitioner also alleged that the Independent Expert Committee constituted by the Drugs Controller of India neither heard him nor physically examined him before it submitted its report, said the petitioner asking the Court to form an Expert committee to go into the issue and submit its report pending l disposal of the Writ Petition.


How the story unfolded

The petitioner had signed the consent form on September 29 as a volunteer.

Since the test for antibodies against Covid-19 was negative, Covishield study vaccine was given to him on October.

Petitioner claims he fell sick 10 days after the shot in clinical trial (it could be the vaccine or the placebo).

However, since follow-up tests showed he had developed antibodies for Sars-CoV-2 virus, there is a high probability that he was given the vaccine shot.

Ten days later, on October 11, the person reported severe headache and vomited. After CT scans, Covid-19 tests and MRI scans, he was admited to the intensive care unit of a hospital.

He was discharged after 11 days; discharge summary says he had suffered “acute encephalopathy”. The person is still disoriented and agitated.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, February 19 2021. 15:00 IST
RECOMMENDED FOR YOU